| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/20/2004 | EP1467989A1 Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection |
| 10/20/2004 | EP1467982A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof |
| 10/20/2004 | EP1467981A1 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| 10/20/2004 | EP1467979A2 FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION |
| 10/20/2004 | EP1467978A1 Pancreatic lipase inhibitor compounds, their synthesis and use |
| 10/20/2004 | EP1467977A1 Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them. |
| 10/20/2004 | EP1467976A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 10/20/2004 | EP1467974A1 Benzimidazole derivatives and their use as gnrh antagonists |
| 10/20/2004 | EP1467972A1 Indazole compounds useful as protein kinase inhibitors |
| 10/20/2004 | EP1467970A1 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| 10/20/2004 | EP1467969A2 Dna minor groove binding compounds |
| 10/20/2004 | EP1467968A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 10/20/2004 | EP1467967A1 Compounds for modulating cell proliferation |
| 10/20/2004 | EP1467965A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 10/20/2004 | EP1467964A1 Polymorphic forms of nateglinide |
| 10/20/2004 | EP1467773A1 Infection-resistant medical devices |
| 10/20/2004 | EP1467770A1 Pantoprazole cyclodextrin inclusion complexes |
| 10/20/2004 | EP1467769A1 A method for preparing resinates |
| 10/20/2004 | EP1467768A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue |
| 10/20/2004 | EP1467767A2 Methods for treating conditions,disorders,or diseases involving cell death |
| 10/20/2004 | EP1467765A2 Combination therapy for the treatment of bacterial infections |
| 10/20/2004 | EP1467764A1 Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 10/20/2004 | EP1467763A1 Methods for treatment of multiple sclerosis with statins |
| 10/20/2004 | EP1467762A1 Use of an h1 antagonist and a safe steroid to treat rhinitis |
| 10/20/2004 | EP1467761A1 Treatment of neovascular ophthalmic disease |
| 10/20/2004 | EP1467760A2 Systems and methods for photodynamic therapy |
| 10/20/2004 | EP1467758A2 Methods for preparing immunoconjugates |
| 10/20/2004 | EP1467754A1 Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus |
| 10/20/2004 | EP1467752A1 HUMAN MAST CELL−EXPRESSED MEMBRANE PROTEINS |
| 10/20/2004 | EP1467750A1 Orodispersible pharmaceutical composition comprising perindopril |
| 10/20/2004 | EP1467744A2 Aqueous compositions containing metronidazole |
| 10/20/2004 | EP1467743A1 Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application |
| 10/20/2004 | EP1467742A1 Use of alkylphosphocholines for the preventative treatment of protozoan diseases |
| 10/20/2004 | EP1467741A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 10/20/2004 | EP1467740A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 10/20/2004 | EP1467739A2 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators |
| 10/20/2004 | EP1467738A1 Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
| 10/20/2004 | EP1467737A1 Orally dispersible pharmaceutical piribedil composition |
| 10/20/2004 | EP1467736A2 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| 10/20/2004 | EP1467735A2 Polymorphs of clopidogrel hydrogensulfate |
| 10/20/2004 | EP1467734A1 Cotherapy with an oxazolidinone and a vitamin b |
| 10/20/2004 | EP1467733A1 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 10/20/2004 | EP1467732A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 10/20/2004 | EP1467731A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 10/20/2004 | EP1467730A1 Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| 10/20/2004 | EP1467729A1 Beta-secretase inhibitors |
| 10/20/2004 | EP1467728A1 Pharmaceutical compositions comprising valsartan and nep inhibitors |
| 10/20/2004 | EP1467725A1 Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol |
| 10/20/2004 | EP1467724A1 Orodispersible pharmaceutical composition comprising agomelatine |
| 10/20/2004 | EP1467723A1 Phenyl sulfoxides and phenyl sulfones |
| 10/20/2004 | EP1467722A2 Use of an anti-microtubule agent for the treatment of uveitis |
| 10/20/2004 | EP1467721A2 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 10/20/2004 | EP1467720A2 Dna dosage forms |
| 10/20/2004 | EP1467718A1 Method of treatment of a patient requiring analgesia |
| 10/20/2004 | EP1467717A1 Stable pharmaceutical compositions comprising ace inhibitor(s) |
| 10/20/2004 | EP1467715A1 Formulations for oral administration of active compounds |
| 10/20/2004 | EP1467714A1 Drug mixture with enhanced dissolution rate |
| 10/20/2004 | EP1467712A1 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| 10/20/2004 | EP1467711A2 Dna dosage forms |
| 10/20/2004 | EP1467710A2 Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support |
| 10/20/2004 | EP1467707A1 Composition for easing human childbirth |
| 10/20/2004 | EP1467706A2 Dermal application system for aminolevulinic acid-derivatives |
| 10/20/2004 | EP1467705A2 Therapeutic agent delivery tampon |
| 10/20/2004 | EP1467701A2 Compositions and methods for high sorption of skin materials and delivery of sulfur |
| 10/20/2004 | EP1467695A2 Hiv integrase inhibitors |
| 10/20/2004 | EP1467625A1 Adhesion inhibition of moulds |
| 10/20/2004 | EP1467622A2 Mitocidal compositions and methods |
| 10/20/2004 | EP1368327B1 Benzo thiadiazine matrix metalloproteinase inhibitors |
| 10/20/2004 | EP1351669B1 Clear propofol compositions |
| 10/20/2004 | EP1307264B1 New pharmaceutical composition |
| 10/20/2004 | EP1305033B1 Pharmaceutical compositions containing tobramycin and xanthan gum |
| 10/20/2004 | EP1289964B1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
| 10/20/2004 | EP1289936B1 Substituted stilbenes as glucose uptake enhancers |
| 10/20/2004 | EP1282611B1 Substituted phenylacetamides and their use as glucokinase activators |
| 10/20/2004 | EP1263725B1 Novel compounds |
| 10/20/2004 | EP1261588B1 IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS |
| 10/20/2004 | EP1252194B1 Use of heparin with average molecular mass |
| 10/20/2004 | EP1246619B1 Urotensin-ii receptor antagonists |
| 10/20/2004 | EP1233954B1 A process for the preparation of 2- 4-(alpha-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy acetic acid and novel intermediates therefor |
| 10/20/2004 | EP1230236B1 Compound with growth hormone releasing properties |
| 10/20/2004 | EP1217902B1 Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions |
| 10/20/2004 | EP1212337B1 Pesticidal macrolides |
| 10/20/2004 | EP1206473B1 Isomeric fused pyrrolocarbazoles and isoindolones |
| 10/20/2004 | EP1206268B1 Novel compositions for controlled release of a biologically active agent, and the preparation thereof |
| 10/20/2004 | EP1204660B1 Serotonergic benzothiophenes |
| 10/20/2004 | EP1194115B1 Topically applied idebenone-containing agent with protective and regenerative effect |
| 10/20/2004 | EP1183015B1 Multilayered tablet for administration of a fixed combination of tramadol and diclofenac |
| 10/20/2004 | EP1161239B1 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis |
| 10/20/2004 | EP1157005B1 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
| 10/20/2004 | EP1149074B1 Acetylenic sulfonamide thiol tace inhibitors |
| 10/20/2004 | EP1143967B1 Use of anticonvulsant derivatives for treating cluster headaches |
| 10/20/2004 | EP1140941B1 Nitrogen containing heterobicycles as factor xa inhibitors |
| 10/20/2004 | EP1135112B1 An oral formulation for gastrointestinal drug delivery |
| 10/20/2004 | EP1131291B1 4-aroyl-piperidin-ccr-3 receptor antagonists iii |
| 10/20/2004 | EP1117416B1 Plant extracts for the treatment of increased bone resorption |
| 10/20/2004 | EP1112253B1 Branched alkyl pyrrolidine-3-carboxylic acids |
| 10/20/2004 | EP1091740B1 Semi-solid aqueous preparations for oral applications of toltrazuril sulphone |
| 10/20/2004 | EP1079815B1 Timed-release transdermal systems containing an active ingredient |
| 10/20/2004 | EP1073440B1 sPLA 2 INHIBITOR ESTERS |
| 10/20/2004 | EP1071667A4 Receptor ligands |